

## TABLE OF CONTENTS

|  |            |
|--|------------|
| <b>LIST OF TABLES</b>                                  | <b>vii</b> |
| <b>LIST OF FIGURES</b>                                 | <b>ix</b>  |
| <b>EXECUTIVE SUMMARY AND HIGHLIGHTS</b>                | <b>1</b>   |
| <b>1. MARKET</b>                                       | <b>7</b>   |
| 1.1 Scope and definition                               | 7          |
| 1.1.1 Revisions  | 7          |
| 1.1.2 Estimates for clinics                            | 7          |
| 1.1.3 Market shares                                    | 7          |
| 1.1.4 Projections                                      | 8          |
| 1.2 Private acute medical care providers – market size | 8          |
| 1.3 Private acute medical hospitals and clinics market | 8          |
| 1.3.1 Market size and growth trends                    | 8          |
| 1.3.2 Covid 2020 update                                | 11         |
| 1.3.3 Provider (value) market shares                   | 11         |
| 1.4 Private patients only (PPO) hospital market        | 12         |
| 1.4.1 Market size and growth trends                    | 12         |
| 1.4.1.1 Covid 2020 update                              | 13         |
| 1.5 NHS Private Patients                               | 14         |
| 1.5.1 Market size and growth trends                    | 14         |
| 1.5.1.1 Covid 2020 update                              | 15         |
| 1.5.2 Regional trends                                  | 16         |
| 1.5.3 Future trends and prospects                      | 18         |
| 1.6 Other private acute medical care components        | 18         |
| 1.6.1 Screening  | 18         |
| 1.6.1.1 Covid 2020 update                              | 20         |
| 1.6.2 Fertility treatments                             | 20         |
| 1.6.2.1 Covid 2020 update                              | 22         |
| 1.6.3 Pregnancy terminations                           | 22         |
| 1.7 Specialists' private practice fee income           | 24         |
| 1.7.1 Covid 2020 Update                                | 25         |

---

|           |  |           |
|-----------|--|-----------|
| 1.8       | Funding by payor type – independent acute healthcare hospitals and clinics           | 25        |
| 1.8.1     | Self-pay spending – mainstream (non-cosmetic) spending and cosmetic surgery revenues | 26        |
| 1.9       | Private acute medical care – market structure and activity overview                  | 27        |
| 1.9.1     | Regional breakdown of capacity – mainstream independent sector hospitals             | 28        |
| 1.9.2     | Sub-regional capacity in London, the South East and East of England                  | 28        |
| 1.9.3     | Capacity trends over time – independent sector hospitals and clinics                 | 29        |
| 1.10      | Activity – independent sector’s patient admissions                                   | 31        |
| 1.10.1    | UK private acute healthcare sector – PHIN private patient activity data              | 31        |
| 1.10.2    | Independent sector’s share of admissions   | 33        |
| 1.11      | Market structure of Private Patient Units and structural trends                      | 35        |
| 1.11.1    | Regional structural trends   | 37        |
| 1.12      | Staffing – specialists   | 38        |
| 1.12.1    | Consultant supply and private practice   | 38        |
| 1.12.2    | Future supply of private practice  | 39        |
| 1.13      | Performance measures   | 41        |
| 1.13.1    | Profitability of the independent sector  | 41        |
| 1.13.2    | Quality – CQC judgements   | 44        |
| <b>2.</b> | <b>POLITICS AND REGULATION</b>   | <b>49</b> |
| 2.1       | Overview   | 49        |
| 2.1.1     | Covid Timeline   | 49        |
| 2.2       | Key impacts from government policy   | 53        |
| 2.2.1     | NHS use of the independent sector  | 54        |
| 2.2.2     | Patient choice and best provider   | 56        |
| 2.2.3     | Independent sector NHS partnership opportunities                                     | 58        |
| 2.3       | Historic government policy   | 60        |
| 2.3.1     | Emergence and development of private acute medical care 1973–1997                    | 60        |
| 2.3.2     | Philosophical opposition to private healthcare under Labour 1997–2000                | 60        |
| 2.3.3     | Engaging the independent sector to upscale NHS performance 2000–2010                 | 60        |
| 2.3.4     | The Coalition government – reforms in action, 2010–2015                              | 62        |
| 2.3.5     | Political environment for the NHS under Theresa May                                  | 62        |
| 2.3.6     | Labour Party policy for the NHS in 2019  | 63        |

|           |  |           |
|-----------|--|-----------|
| 2.4       | Regulation of the independent acute medical care sector                          | 64        |
| 2.4.1     | Overview   | 64        |
| 2.4.2     | Regulation of quality standards by the Care Quality Commission                   | 65        |
| 2.4.2.1   | Scope of independent acute medical care regulation in England                    | 65        |
| 2.4.2.2   | Outside the scope of regulation  | 66        |
| 2.4.2.3   | The essential standards in England   | 66        |
| 2.4.2.4   | Care Quality Commission developments for independent acute hospitals and clinics | 67        |
| 2.4.3     | Covid impact   | 68        |
| 2.5       | The quality agenda   | 70        |
| 2.5.1     | New developments   | 71        |
| 2.5.2     | PHIN and performance data  | 73        |
| 2.6       | Competition investigations   | 75        |
| 2.6.1     | Office of Fair Trading   | 75        |
| 2.6.2     | Competition and Markets Authority (previously Competition Commission)            | 76        |
| 2.6.2.1   | Remedies and author's view   | 77        |
| 2.6.2.2   | Remittal and appeals   | 78        |
| 2.6.2.3   | Case investigation – private ophthalmology services                              | 78        |
| <b>3.</b> | <b>PAYORS</b>  | <b>81</b> |
| 3.1       | Private medical cover  | 81        |
| 3.1.1     | Covid 2020 update  | 81        |
| 3.1.2     | 2021 progress  | 82        |
| 3.1.3     | Pre-Covid trends in private medical cover  | 82        |
| 3.1.4     | Private medical cover market structure   | 85        |
| 3.1.5     | Future prospects for private medical cover demand                                | 86        |
| 3.2       | NHS purchasing   | 88        |
| 3.2.1     | Market value and trends  | 88        |
| 3.2.1.1   | Covid 2020 update  | 88        |
| 3.2.2     | Activity and provider shares – hospital admissions                               | 90        |
| 3.2.3     | Admissions by specialty  | 94        |
| 3.2.4     | Activity and provider shares – diagnostics                                       | 95        |
| 3.2.5     | Future prospects and trends  | 97        |
| 3.3       | Self-pay patients  | 98        |

---

|           |  |            |
|-----------|--|------------|
| 3.3.1     | Market value and growth trends   | 98         |
| 3.3.1.1   | 2020 Covid update  | 99         |
| 3.3.2     | Provider self-pay trends   | 99         |
| 3.3.3     | Regional trends – London v rest of UK                                    | 100        |
| 3.3.4     | Historic trends  | 102        |
| 3.3.5     | NHS performance – waiting and treatment restrictions                     | 103        |
| 3.3.6     | Future prospects and trends  | 109        |
| 3.3.7     | Cosmetic surgery   | 110        |
| 3.3.8     | Cosmetic surgery – future prospects and trends                           | 112        |
| 3.4       | Overseas   | 113        |
| 3.4.1     | Market size and growth trends  | 113        |
| 3.4.2     | Covid 2020 update  | 113        |
| 3.4.3     | Projections and prospects  | 114        |
| <b>4.</b> | <b>MAJOR PROVIDERS</b>   | <b>117</b> |
| 4.1       | Independent sector – market concentration and shares                     | 117        |
| 4.2       | Independent sector – provider type                                       | 121        |
| 4.3       | New independent acute medical capacity and structural trends             | 123        |
| 4.3.1     | Capital investment by incumbents   | 129        |
| 4.3.1.1   | Partnership investment   | 130        |
| 4.3.2     | Full-service and specialist inpatient acute hospitals                    | 131        |
| 4.3.3     | Day surgery only including specialist facilities                         | 133        |
| 4.3.4     | New day surgery eye hospitals  | 135        |
| 4.3.5     | Outpatient and diagnostic clinics  | 136        |
| 4.3.6     | Specialist outpatient clinics  | 138        |
| 4.3.7     | Insourcing and other independent sector management of NHS acute services | 140        |
| 4.3.8     | Closures   | 142        |
| 4.4       | NHS providers – private income market shares                             | 142        |
| 4.4.1     | Specialisation   | 144        |
| 4.4.2     | NHS PPUs during the Covid pandemic                                       | 145        |
| 4.4.3     | New NHS private patient facilities including partnerships                | 145        |
| 4.5       | Other acute markets  | 148        |
| 4.5.1     | Screening  | 148        |

---

|           |  |            |
|-----------|--|------------|
| 4.5.2     | Fertility  | 150        |
|           | 4.5.2.1 Covid 2020 update                        | 152        |
| 4.5.3     | Pregnancy terminations                           | 153        |
| <b>5.</b> | <b>INVESTORS</b>                                 | <b>155</b> |
| 5.1       | Major investor review                            | 155        |
| 5.1.1     | Nordic Capital                                   | 157        |
| 5.1.2     | Palatine Private Equity                          | 157        |
| 5.1.3     | TriSpan  | 157        |
| 5.1.4     | H2 Equity Partners                               | 158        |
| 5.1.5     | Hospital Topco Ltd                               | 158        |
| 5.1.6     | Mediclinic International                         | 159        |
| 5.1.7     | HCA Healthcare Inc.                              | 159        |
| 5.1.8     | Bridgepoint Capital                              | 160        |
| 5.1.9     | Centene Corporation                              | 160        |
| 5.1.10    | NMC Health plc                                   | 161        |
| 5.1.11    | Aurelius   | 161        |
| 5.1.12    | Fidelity International                           | 161        |
| 5.1.13    | RCapital   | 162        |
| 5.1.14    | BlueGem Capital Partners                         | 162        |
| 5.1.15    | Life Healthcare                                  | 162        |
| 5.1.16    | China Resources Group & Macquarie Group          | 163        |
| 5.1.17    | Apposite Capital                                 | 163        |
| 5.1.18    | CBPE Capital                                     | 163        |
| 5.1.19    | Schroders UK Public Private Trust                | 164        |
| 5.1.20    | Investors in the fertility sector                | 164        |
| 5.2       | Recent acquisitions in the sector                | 164        |
| <b>6.</b> | <b>MARKET POTENTIAL</b>                          | <b>169</b> |
|           | <b>APPENDIX 1. GLOSSARY</b>                      | <b>171</b> |
|           | <b>APPENDIX 2. KEY LEGISLATION</b>               | <b>175</b> |
|           | <b>APPENDIX 3. REGULATORS</b>                    | <b>177</b> |
|           | <b>APPENDIX 4. TRADE BODIES AND ASSOCIATIONS</b> | <b>179</b> |

|   |            |
|---|------------|
| <b>APPENDIX 5. MAJOR INDEPENDENT HEALTHCARE PROVIDERS</b>                               | <b>181</b> |
| <b>APPENDIX 6. LIST OF PRIVATE PATIENT UNITS (WITH OVERNIGHT BEDS)</b>                  | <b>211</b> |
| <b>APPENDIX 7. FINAL CONCLUSIONS OF THE CMA'S INVESTIGATION INTO PRIVATE HEALTHCARE</b> | <b>215</b> |
| <b>APPENDIX 8. FINANCIAL APPENDIX</b>   | <b>219</b> |

## LIST OF TABLES

|            |   |    |
|------------|---|----|
| Table 1.1  | Private acute medical care hospital market value (independent acute medical hospitals and clinics, and NHS private patients), UK, 2003–2019 and 2020 projections  | 10 |
| Table 1.2  | Private patients only hospital market value (independent acute medical hospitals and clinics' private patients and NHS private patients), UK, 2003–2019 and 2020 projections  | 14 |
| Table 1.3  | NHS private patient revenues, UK, 1990/91–2019/20   | 17 |
| Table 1.4  | NHS private patient revenues and real growth, by UK region, 2016/17–2019/20   | 18 |
| Table 1.5  | Screening spending (market size), real growth and real index, UK, 2000–2019   | 19 |
| Table 1.6  | Overall trends in fertility treatment, all sectors, UK, 2008–2019   | 21 |
| Table 1.7  | Trends in fertility treatment by funding sector, UK, 2008–2019  | 21 |
| Table 1.8  | Number of independent sector abortions in England & Wales, and estimated UK independent sector clinic revenues, 2003–2020   | 22 |
| Table 1.9  | Independent acute medical hospitals and clinics market value and revenues by purchaser, UK, 2003–2019 and 2020 projections  | 26 |
| Table 1.10 | Regional share of 'mainstream' independent acute medical care hospitals, share of overnight bed capacity, and share of operating theatres, UK, August 2021  | 28 |
| Table 1.11 | Independent acute medical care hospitals and overnight beds, UK 1981–2021   | 30 |
| Table 1.12 | Private episodes in UK independent sector and NHS hospitals (PHIN data), calendar 2020, and financial year 2019/20 by type of hospital facility   | 32 |
| Table 1.13 | Private episodes in calendar 2020 (PHIN data) – Top 20 inpatient independent sector hospitals, Top ten day/outpatient clinics and top ten NHS facilities, UK  | 34 |
| Table 1.14 | Private episodes in calendar 2020 and between April-June inclusive 2020 by treatment category (PHIN data)   | 35 |
| Table 1.15 | Regional breakdown of PPU's with overnight bed capacity, UK, August 2021  | 37 |
| Table 1.16 | EBITDAR margin and pre-tax profit/loss margin for major for-profit hospital operating companies – latest accounting period, and previous two years  | 43 |
| Table 1.17 | Breakdown of (latest) CQC quality assessments of services provided by core independent hospitals in England (independent hospitals with inpatient facilities + day surgery hospitals of leading independent hospital groups)        | 45 |
| Table 1.18 | Breakdown of (latest) CQC quality assessments by inspection area provided by core independent hospitals in England (independent hospitals with inpatient facilities + day surgery hospitals of leading independent hospital groups) | 46 |
| Table 1.19 | Overall (latest) CQC quality assessments for core independent hospitals in England (independent hospitals with inpatient facilities + day surgery hospitals of leading independent hospital groups) by hospital provider            | 46 |
| Table 2.1  | Overall CQC quality ratings of core services for NHS hospitals and independent sector acute hospitals, as at 31 March 2020 and 31 July 2019   | 69 |

|            |   |     |
|------------|---|-----|
| Table 3.1  | Private medical cover persons covered, payouts (claims paid), and average price for private medical cover policy, 1995–2018   | 83  |
| Table 3.2  | NHS purchasing of independent acute medical care services, UK, 2003–2019  | 89  |
| Table 3.3  | NHS funded hospital admissions for acute medical care in the independent sector in England, 2004/05–2020/21   | 91  |
| Table 3.4  | NHS funded admissions treated by independent sector (IS) providers by type of speciality – specialty share, proportion of all NHS – in 2019/20  | 96  |
| Table 3.5  | NHS funded (provider based) diagnostic procedures/tests carried out by the independent sector, England, 2009/10–2020/21   | 97  |
| Table 3.6  | Private self-pay spending on acute medical care services in independent sector hospitals and clinics, including non-cosmetic and cosmetic split, UK, 2003–2019                          | 100 |
| Table 3.7  | Proportion of self-financed treatment episodes in independent hospitals for 1981–1997/98 (England and Wales), 2001–2019 (UK)  | 103 |
| Table 4.1  | Independent sector acute medical care providers by provider grouping, UK, August 2021   | 117 |
| Table 4.2  | Capacity of major acute medical care hospital operators by number of overnight hospitals, overnight (inpatient) beds, and total operating theatres (OTs) in all facilities, August 2021 | 118 |
| Table 4.3  | Top 30 independent acute medical care hospital providers by revenue, 2013–2020 (calendar year unless otherwise stated), and 2019 market share   | 119 |
| Table 4.4  | Bed and revenue shares of the UK independent acute medical care hospital sector (excluding day only operators) by provider affiliation, as at August 2021                               | 122 |
| Table 4.5  | New independent acute medical care facilities by region, service type (full-service or specialist) and treatment type (inpatient/day/outpatient), UK, from 2014 onwards                 | 125 |
| Table 4.6  | New independent acute eye care facilities by region, service type, and treatment type (inpatient/day/outpatient), UK, from 2014 onwards   | 127 |
| Table 4.7  | Future new independent acute medical care facilities in the UK by region, service type (full-service or specialist) and treatment type (inpatient/day/outpatient), from 2018 onwards    | 129 |
| Table 4.8  | Top 30 private patient Trust earners, annual growth and % share of UK NHS market, 2019/20 and 2018/19   | 143 |
| Table 4.9  | Revenues of leading specialist IVF providers, UK, 2016–2020   | 152 |
| Table 5.1  | Main investors in the UK private acute medical care market, including source country, and investment start, August 2021   | 156 |
| Table 5.2  | Significant acquisitions in private acute medical care market, UK, 2015 onwards   | 166 |
| Table A7.1 | Competition and Markets Authority investigation into private healthcare – final conclusions, April 2014   | 215 |
| Table A7.2 | Competition and Markets Authority investigation into private healthcare – remedies recommended, April 2014  | 217 |



## LIST OF FIGURES

|             |   |    |
|-------------|---|----|
| Figure 1.1  | Private acute medical care market value by component, UK, 2019  | 9  |
| Figure 1.2  | Market shares (%) of private acute medical care hospital market (independent sector hospitals and clinics + NHS private patient revenues) by provider, UK, 2019               | 12 |
| Figure 1.3  | Real value index – private acute medical care market, and private patient only (PPO) hospital market, UK, 2003–2019   | 13 |
| Figure 1.4  | Market shares of the PPO hospital market by provider, UK, 2019  | 15 |
| Figure 1.5  | Legal abortions carried out in England and Wales, 1968–2020   | 23 |
| Figure 1.6  | Segmentation of public and private activity: abortions, England and Wales residents, 2020   | 24 |
| Figure 1.7  | Capacity indicators (overnight hospitals (H), overnight beds (B) & operating theatres (OT)) by sub-region in London, the South East and East of England, August 2021          | 29 |
| Figure 1.8  | PHIN's monthly private admission activity as a percentage of a year earlier, January 2020 to February 2021  | 33 |
| Figure 1.9  | UK hospital (inpatient and day case) surgical activity breakdown by type of hospital supply (public NHS or private) and type of funding (public NHS or private), 1986–2019/20 | 35 |
| Figure 1.10 | EBITDAR margin of leading independent sector hospital groups, 2008–2020   | 44 |
| Figure 3.1  | Healthcode's monthly PMI (private medical insurance) billing activity in 2020 as a percentage of 2019   | 81 |
| Figure 3.2  | Market shares for total private medical cover market spending: insured premium income plus self-insured (Healthcare Trusts) derived spending combined, calendar 2017          | 85 |
| Figure 3.3  | Market shares of NHS revenues generated by independent sector hospitals and clinics by provider, 2019   | 90 |
| Figure 3.4  | Monthly NHS funded elective surgery (provider based) admissions in independent sector in England, January 2013–March 2020 (discontinued data series)                          | 92 |
| Figure 3.5  | Monthly NHS funded elective surgery (provider based) admissions in independent sector in England, January 2018–June 2021 (new data series)                                    | 92 |
| Figure 3.6  | NHS funded acute medical care hospital admissions in independent sector, by provider, England, 2019/20 – pre-Covid  | 93 |
| Figure 3.7  | NHS funded acute medical care hospital admissions in independent sector in England in 2020/21 by provider   | 94 |
| Figure 3.8  | NHS funded admissions treated by independent sector (IS) providers by type of specialty, 2019/20  | 95 |

---

|             |   |     |
|-------------|---|-----|
| Figure 3.9  | NHS funded diagnostic procedures provider in the independent sector in England by provider group, 2020/21 (2019/20 in brackets)   | 98  |
| Figure 3.10 | GVA (Gross Value Added) growth , London and rest of UK, 1998–2019   | 101 |
| Figure 3.11 | Number of NHS patients waiting for start of treatment, and average (median) time waited in England, March 2008–July 2021  | 104 |
| Figure 3.12 | Waiting time from GP referral to hospital treatment for NHS admitted patients in England – Average (median) number of weeks of waiting and percentage of patients waiting more than 18 weeks, March 2008–July 2021                  | 105 |
| Figure 3.13 | NHS patients waiting for start of treatment by region share at June 2021  | 106 |
| Figure 3.14 | Average (median), lowest and highest number of weeks of waiting from GP referral to treatment (admission) on NHS by region, June 2021   | 107 |
| Figure 3.15 | Average (median) waiting time from GP referral to hospital treatment for NHS admitted patients in England at June 2021 by type of treatment, and percentage change in average waiting over the past 60 months (June 2016–June 2021) | 108 |
| Figure 3.16 | Annual growth in plastic surgery procedures reported by BAAPS members, 2004–2020  | 111 |
| Figure 3.17 | Share of plastic surgery activity carried out by BAAPS members by type of procedure, 2015 and 2020  | 112 |
| Figure 4.1  | Market shares of top ten hospital providers in private patient only independent acute medical care market, UK, 2019   | 121 |